Figure 9 is a forest plot (i.e., a graph that depicts a meta-analysis plot) showing the individual and pooled relative risks and 95% confidence intervals (random effects model) from 2 trials for the comparison of 4 weeks of dual therapy lead-in followed by 44 weeks of triple therapy with boceprevir versus 48 weeks of dual therapy in patients with genotype 1 infection on sustained virological response In the center of the graph is a solid vertical line corresponding to no effect. The individual studies are depicted at varying distances along this line as horizontal lines with a solid square in the middle. The size of the square varies in relation to the size of the study and the weight of the individual study in the overall analysis. The pooled effect is represented by a diamond at the bottom of the graph. Based on data from both trials, triple therapy was associated with an increased likelihood of SVR compared to dual therapy. The relative risk estimates ranged from 1.75 (95% confidence interval 1.52–2.04) to 1.99 (95% confidence interval 1.52–2.62). The pooled relative risk was 1.80, with a 95% confidence interval of 1.6 to 2.1; I-squared = 0.0 %, p = 0.416.

Figure 9Sustained virologic response: 48 weeks of triple therapy with boceprevir (4 weeks of dual therapy lead-in with pegylated interferon alfa-2b followed by the addition of 44 weeks boceprevir) versus 48 weeks of dual therapy in patients with genotype 1 infection

From: Results

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.